已收盤 02-06 16:00:00 美东时间
+0.110
+2.26%
今日重点评级关注:Benchmark:维持TNL Mediagene"投机性买入"评级,目标价从3.5美元升至14美元;康托·菲茨杰拉德:维持Eupraxia Pharmaceuticals"超配"评级,目标价从11美元升至19美元
01-16 10:04
UBS analyst Leonardo Olmos upgrades CI&T (NYSE:CINT) from Neutral to Buy and raises the price target from $6.8 to $7.
01-15 21:16
今日重点评级关注:HC Wainwright & Co.:维持PDS Biotechnology"买入"评级,目标价从13美元升至15美元;HC Wainwright & Co.:维持PepGen Inc."买入"评级,目标价从18美元升至20美元
2025-11-14 10:43
JP Morgan analyst Puneet Jain maintains CI&T (NYSE:CINT) with a Overweight and lowers the price target from $8 to $7.
2025-11-14 03:11
CI&T (NYSE:CINT) sees Q4 sales of $130.400 million-$132.600 million vs $131.437 million analyst estimate.
2025-11-13 05:14
CI&T (NYSE:CINT) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.10 by 9.09 percent. This is a 28.57 percent increase over earnings of $0.07 per share from the same period
2025-11-13 05:13
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
Gainers SMX (Security Matters) (NASDAQ:SMX) stock increased by 11.9% to $2.26 ...
2025-11-01 05:07
今日重点评级关注:Rosenblatt:维持HIVE Digital Technologies"买入"评级,目标价从5美元升至10美元;摩根大通:维持Array Technologies"超配"评级,目标价从13美元升至15美元
2025-10-17 09:58
Canaccord Genuity analyst Luke Morison maintains CI&T (NYSE:CINT) with a Buy and maintains $8 price target.
2025-10-16 22:16